VTRS
ViatrisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The Q1 print and guidance reaffirmation suggest Viatris can still deliver operating leverage, while Greater China and branded-drug strength provide near-term support. The meloxicam NDA adds a discrete pipeline readout that could widen the valuation range if it clears FDA review.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Fast-acting meloxicam is still a binary FDA review until the Dec. 27, 2026 PDUFA date.
Momentum
49
Value
66
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.80 · Bull $19.00 · Bear $12.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.00
Why
Momentum49 · Δ7d +3.8
Value66 · Δ7d -0.3
Sentiment37 · Δ7d -8.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
49
26% active weight
Current posture
7d trendImproving
Δ7d
+3.8
Δ21d
-21.3
Value
66
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.4
Sentiment
37
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.8
Δ21d
-6.8
Why this grade
Composite grade C. Momentum 48.7 / Value 65.8 / Sentiment 36.9
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$19.94B
Beta
0.78
Shares Out
1.17B
P/E (TTM) · Derived
-5.7
P/S (TTM)
1.01
P/FCF (TTM)
13.63
Rev YoY
+8.5%
EPS YoY
-105.9%
Gross Margin
+38.9%
Op Margin
-21.3%
Net Debt
$13.25B
Current Ratio
1.52
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology